Tvardi Therapeutics Inc.

06/11/2026 | Press release | Distributed by Public on 06/11/2026 14:06

Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 9, 2026, Tvardi Therapeutics, Inc. (the "Company") held its Annual Meeting of Stockholders (the "Annual Meeting"). At the Annual Meeting, the Company's stockholders voted on the four proposals set forth below. A more detailed description of each proposal is set forth in the Company's Proxy Statement filed with the Securities and Exchange Commission on April 23, 2026.

Proposal 1 - Election of Directors

Imran Alibhai, Ph.D., Cynthia Smith and Sujal Shah were each elected to serve as a Class II director of the Company's Board of Directors until the 2029 Annual Meeting of Stockholders and until their successor is duly elected or until their earlier resignation or removal, by the following votes:

Nominee Votes For Votes Withheld
Imran Alibhai, Ph.D. 3,513,039 147,472
Cynthia Smith 3,392,877 267,634
Sujal Shah 3,507,652 152,859

Broker Non-Votes: 2,975,429

Proposal 2 - Non-Binding, Advisory Vote on Executive Compensation

The stockholders approved, on a non-binding advisory basis, the compensation of the Company's named executive officers, by the following votes:

Votes For Votes Against Abstentions Broker Non-Votes
3,482,265 161,795 16,451 2,975,429

Proposal 3 - Advisory Vote on the Frequency of Solicitation of Advisory Stockholder Approval of Executive Compensation

The stockholders indicated, on an advisory basis, one year as the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers, by the following votes:

1 Year 2 Years 3 Years Abstentions Broker Non-Votes
3,453,729 9,343 15,435 182,004 2,975,429

In accordance with the recommendation of the Company's Board of Directors and based on the results of the advisory vote reported above, the Company has determined that it will hold future advisory votes on the compensation of the Company's named executive officers on an annual basis until the next required advisory vote on the frequency of stockholder advisory votes on the compensation of the Company's named executive officers.

Proposal 4 - Ratification of the Selection of Independent Registered Public Accounting Firm

The stockholders ratified the selection by the Audit Committee of the Board of Directors of the Company of Deloitte & Touche LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2026, by the following votes:

Votes For Votes Against Abstentions Broker Non-Votes
6,523,292 62,646 50,002 -
Tvardi Therapeutics Inc. published this content on June 11, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on June 11, 2026 at 20:06 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]